Drugs in MeSH Category Calcium Channel Blockers

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	CALAN SR	verapamil hydrochloride	TABLET, EXTENDED RELEASE;ORAL	019152-002	Dec 15, 1989		DISCN	Yes	No
Hospira	VERAPAMIL HYDROCHLORIDE	verapamil hydrochloride	SOLUTION;INTRAVENOUS	070737-002	May 6, 1987	AP	RX	No	Yes
Ph Health	NIFEDIPINE	nifedipine	TABLET, EXTENDED RELEASE;ORAL	077899-003	May 25, 2012		DISCN	No	No
Torrent	PREGABALIN	pregabalin	CAPSULE;ORAL	206942-008	Feb 21, 2025	AB	RX	No	No

Last updated: July 2, 2026

Market dynamics and patent landscape for calcium channel blockers (MeSH): which drugs still have patent and regulatory exclusivity?

Calcium channel blockers (CCBs) remain a large, mature cardiovascular class with pricing pressure from generics and wide formulary penetration. Patent value concentrates in (1) extended-release (ER) and delivery-platform improvements, (2) combination products (CCB plus ACE inhibitor or statin-class components), and (3) select next-generation molecules with residual new-use or process protection in branded markets. Across the class, most “base” generics have no meaningful remaining FDA exclusivity; the investable IP sits in formulation, method-of-manufacture, or specific dosing regimens that delay FDA-driven generic substitution and create litigation leverage in Paragraph IV pathways.

At a high level

• Dihydropyridines (e.g., amlodipine, nifedipine-class, felodipine, isradipine) face intense generic competition. IP tends to be strongest in ER formulations and line extensions rather than the first-generation active.
• Non-dihydropyridines (verapamil, diltiazem) have fewer modern entrants; IP is mostly around extended-release products and specific salts/solid forms.
• Combinations (CCB + other cardiovascular agents) can retain market exclusivity longer due to distinct patent families and separate regulatory approvals, even when single-entity CCBs are genericized.

Important limitation: A complete, correct “patent landscape” requires drug-by-drug anchoring to Orange Book listings, exclusivity codes, and specific patent numbers. The provided prompt does not specify which CCBs, which jurisdictions, or which marketed products to cover. Under the operating constraints, no partial or guessed patent data is included.

---

Which calcium channel blockers still have meaningful patent protection in the US?

Featured snippet answer: Patent protection in the US CCB class is most likely to persist for branded products where (a) the formulation is ER and protected by dedicated patent families, (b) the label expansion created distinct method-of-use coverage, or (c) the product is a combination with a non-generic co-formulated component.

What patent themes dominate CCB estates?

• Extended-release (ER) dosage forms
  • Polymer matrix or coated-bead systems
  • Release kinetics targets tied to specific dissolution profiles
• Formulation and solid-state
  • Salt selection, hydrate/polymorph control, particle size distributions
• Method-of-manufacture
  • Granulation, coating, compression tooling, drying parameters
• Combination products
  • Co-crystallization, bilayer tablets, fixed-dose combinations with distinct mechanical or release design

How to gauge residual IP value fast (without full litigation mapping)?

A practical investor/license screen for CCBs:

• Identify whether the branded product is ER vs IR.
• Check whether it is single-entity vs combination.
• Track whether the product has had multiple NDA supplements that introduced new strengths, release designs, or dosing instructions.
• Determine if the product has an active litigation history, usually driven by Paragraph IV ANDA challenges to formulations and manufacturing patents.

---

When does generic entry risk peak for amlodipine, diltiazem, and verapamil?

Featured snippet answer: Generic entry risk peaks when both (1) any remaining formulation or method patents near expiry and (2) regulatory exclusivities (if any) are exhausted for the specific approved strength/dosage form. In most markets, the base actives are already generic, so risk concentrates on ER line extensions and branded combinations.

Timeline mechanics that matter

• Regulatory exclusivity (5-year, 3-year, or other platform exclusivities) can delay ANDA approvals even when listed patents expire.
• Orange Book-listed patents govern Paragraph IV leverage.
• Patent-by-patent expiration creates staggered “windows” per strength and dosage form.

What drives litigation timing in CCB ANDAs?

• Filing often accelerates for products with:
  • Dense ER patent families
  • Prior “designed around” attempts that fail at the formulation level
  • Strong commercial pull-through in high-volume retail channels

---

How many patents cover extended-release calcium channel blocker formulations?

Featured snippet answer: Patent families for CCB ER formulations typically include multiple claims spanning formulation composition, release characteristics, and manufacturing. The count varies by product line, but estates often include 3 to 10+ patent documents in total coverage across composition and process.

Common CCB patent claim types relevant to ANDA challenges

• Composition claims for ER matrix/coatings
• Claims for release rate or dissolution window parameters
• Manufacturing steps tied to granulation/coating conditions
• Method-of-treatment claims only when the label includes distinct regimen language

---

What patent litigation affects generic entry for calcium channel blockers?

Featured snippet answer: The most frequent litigation driver for CCB generics is a Paragraph IV dispute over Orange Book patents linked to ER formulation or manufacturing, not over the fundamental active ingredient alone.

Typical litigation posture in CCB cases

• Brand asserts formulation and method patents
• ANDA filer contests validity and/or non-infringement
• Settlements often produce:
  • Delayed launch dates for a specific ER product strength or dosage form
  • Carve-outs for “design-around” formulations that avoid certain claim elements
  • License terms tied to permitted commercialization timelines

---

What is the Orange Book status of calcium channel blockers?

Featured snippet answer: Most widely used CCB single-entity products are broadly generic in the US; the Orange Book status is product- and strength-specific. The “active” portion of the Orange Book is usually tied to ER versions and combinations rather than immediate-release actives.

Orange Book listings to check per CCB product line

• Patent list number and type (composition, formulation, method, etc.)
• Expiration dates per patent document
• Exclusivity expiration (when present) for the approved NDA/NDA supplement
• Reference product mapping for each dosage form and strength

---

Which companies are challenging calcium channel blocker patents with Paragraph IV ANDAs?

Featured snippet answer: Generic entrants in the CCB class typically include large multiproduct generics and ER-specialist filers. The challenge targets usually concentrate on branded ER tablets and select combination products where formulation patents add meaningful barriers.

Who tends to file and why (structural reasons)

• High-volume retail products with:
  • Patent density in ER formulations
  • Known brand spend and rebate intensity
  • Multiple strengths that enable “first filer” commercial momentum

(No named-company claims are provided because the prompt does not specify which CCBs/products to map to current filings and outcomes.)

---

How does the market share and pricing pressure differ across dihydropyridine vs non-dihydropyridine CCBs?

Featured snippet answer: Market pricing is typically lower for products with deeper generic penetration. Dihydropyridines dominate chronic hypertension and peripheral vascular segments; non-dihydropyridines have more cardiology-specific prescribing patterns. Patent value, when present, concentrates in ER dosing forms in both groups.

Commercial dynamics by subgroup

• Dihydropyridines
  • Large volume, broad primary care use
  • ER products frequently become the last branded lines to face full generic substitution
• Non-dihydropyridines
  • More specialized use cases (rate control, cardiac conduction contexts)
  • ER formulation differentiation can matter for adherence

---

What formulations are protected by calcium channel blocker patents?

Featured snippet answer: CCB patents most commonly protect ER delivery systems: matrix tablets, coated beads, osmotic release systems, and specific manufacturing processes that produce a reproducible dissolution and release profile.

Formulation categories that show up in enforcement

• Matrix ER tablets (polymer-controlled)
• Bead-based ER systems (layered coatings)
• Multi-layer tablets designed to control release sequence
• Solid-state modifications enabling targeted release behavior

---

What method-of-use patents apply to calcium channel blockers?

Featured snippet answer: Method-of-use coverage in CCBs is less frequent than formulation/process coverage because the therapeutic effects and dosing regimens are often standard for the base active ingredients. When present, it usually tracks a label-expanded regimen, titration approach, or a defined patient population.

Why method-of-use can still matter

• Method claims can prevent “at-risk” launches even when formulation design-around succeeds.
• Settlements may address specific label instructions rather than the entire product category.

---

What generic entry risks exist for ER calcium channel blocker products?

Featured snippet answer: The core risk is that the generic ANDA is approved but cannot launch on schedule if a court blocks design-around or if a settlement delays entry. The litigation focus often stays on dissolution/release performance and manufacturing steps.

Launch blocking mechanisms

• Court injunctions tied to claim scope
• Settlement-driven delay terms
• Regulatory or quality issues interacting with patent design-around requirements

---

How do calcium channel blocker combination products change the patent landscape?

Featured snippet answer: CCB combinations often have separate patent estates tied to the fixed-dose design, release alignment, and co-ingredient protection. This can extend brand leverage beyond that of the single active ingredient.

Combination patent themes

• Fixed-dose tableting or multilayer release synchronization
• Combination-specific method-of-manufacture claims
• Co-formulation that reduces bioavailability mismatch risks

---

Key Takeaways

• CCB patent value is concentrated in ER formulations, method-of-manufacture, and combination products rather than the first-generation actives.
• Generic entry risk is strength- and dosage-form-specific; the remaining Orange Book value is usually where ER line extensions still have active patents.
• Litigation commonly targets formulation/process claims in Paragraph IV ANDAs, with settlements that delay launches or permit limited design-around commercialization.
• For a complete, actionable landscape, mapping must be done drug-by-drug to Orange Book patent lists and exclusivity codes for each dosage form and strength.

---

FAQs

1. Which calcium channel blocker patents most often get asserted in ANDA Paragraph IV cases for ER tablets?
2. How do fixed-dose CCB combination products affect Orange Book patent expiration timing compared with single-entity CCBs?
3. What patent claim types (composition, formulation, process, method-of-use) are most relevant to designing around CCB ER patents?
4. What factors determine whether an ANDA filer can launch immediately after patent expiry for an ER CCB?
5. How does FDA exclusivity interact with Orange Book patent expiry for CCBs with multiple NDA supplements?

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. (Website).